304 related articles for article (PubMed ID: 33740661)
21. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
[TBL] [Abstract][Full Text] [Related]
22. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.
Ponz-Sarvise M; Corbo V; Tiriac H; Engle DD; Frese KK; Oni TE; Hwang CI; Öhlund D; Chio IIC; Baker LA; Filippini D; Wright K; Bapiro TE; Huang P; Smith P; Yu KH; Jodrell DI; Park Y; Tuveson DA
Clin Cancer Res; 2019 Nov; 25(22):6742-6755. PubMed ID: 31492749
[TBL] [Abstract][Full Text] [Related]
23. The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells.
Nováková J; Talacko P; Novák P; Vališ K
Cells; 2019 Feb; 8(2):. PubMed ID: 30795621
[TBL] [Abstract][Full Text] [Related]
24. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
25. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
[TBL] [Abstract][Full Text] [Related]
27. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
28. MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.
Ding XZ; Adrian TE
Biochem Biophys Res Commun; 2001 Mar; 282(2):447-53. PubMed ID: 11401480
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.
Aslan O; Cremona M; Morgan C; Cheung LW; Mills GB; Hennessy BT
BMC Cancer; 2018 Feb; 18(1):168. PubMed ID: 29426295
[TBL] [Abstract][Full Text] [Related]
31. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models.
Jiang H; Xu M; Li L; Grierson P; Dodhiawala P; Highkin M; Zhang D; Li Q; Wang-Gillam A; Lim KH
Mol Cancer Ther; 2018 Oct; 17(10):2144-2155. PubMed ID: 30065098
[TBL] [Abstract][Full Text] [Related]
32. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
33. Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells.
Veit C; Genze F; Menke A; Hoeffert S; Gress TM; Gierschik P; Giehl K
Cancer Res; 2004 Aug; 64(15):5291-300. PubMed ID: 15289335
[TBL] [Abstract][Full Text] [Related]
34. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
36. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
37. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
[TBL] [Abstract][Full Text] [Related]
38. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
Williams TM; Flecha AR; Keller P; Ram A; Karnak D; Galbán S; Galbán CJ; Ross BD; Lawrence TS; Rehemtulla A; Sebolt-Leopold J
Mol Cancer Ther; 2012 May; 11(5):1193-202. PubMed ID: 22411900
[TBL] [Abstract][Full Text] [Related]
39. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
Mirzoeva OK; Das D; Heiser LM; Bhattacharya S; Siwak D; Gendelman R; Bayani N; Wang NJ; Neve RM; Guan Y; Hu Z; Knight Z; Feiler HS; Gascard P; Parvin B; Spellman PT; Shokat KM; Wyrobek AJ; Bissell MJ; McCormick F; Kuo WL; Mills GB; Gray JW; Korn WM
Cancer Res; 2009 Jan; 69(2):565-72. PubMed ID: 19147570
[TBL] [Abstract][Full Text] [Related]
40. eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors.
Hijazi M; Casado P; Akhtar N; Alvarez-Teijeiro S; Rajeeve V; Cutillas PR
Mol Cell Proteomics; 2022 Jun; 21(6):100240. PubMed ID: 35513296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
